西妥昔单抗联合塞来昔布对肺腺癌细胞KDR和AQP1表达的影响

背景与目的新辅助化疗是肺癌治疗的新进展，西妥昔单和合塞来昔布均是近年来新辅助化疗的常用药物，本研究旨在探讨表皮生长因子受体（epithelialgrowthfactorreceptor,EGFR）单克隆抗体西妥昔单抗（Cetux-imab）联合环氧合酶2（cyclooxygenase．2，COX-2）抑制剂塞来昔布对肺腺癌A549细胞株凋亡和KDR、AQP1表达的影响。方法A549细胞培养于RPMI-1640培养液中，实验分为正常对照组、西妥昔单抗1nmol／L组、塞来昔布25omol／L组、西妥昔单抗1nmol／L＋塞来昔布25μmol／L组。药物干预细胞48h后，采用四甲基偶氮唑盐比色法测...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 16; no. 12; pp. 625 - 631
Main Author 夏洪刚 叶剑飞 白宏宇 王长利
Format Journal Article
LanguageChinese
Published 300070天津，天津医科大学研究生院 2013
300280天津，天津大港油田总医院胸外科%天津大港油田总医院胸外科,天津,300280%天津市肿瘤医院胸外科,天津,300060
Subjects
AQP1
KDR
塞来昔布
细胞凋亡
西妥昔单抗
细胞凋亡
Cell apoptosis
KDR
塞来昔布
西妥昔单抗
Celecoxib
Cetuximab
AQP1
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2013.12.02

Cover

More Information
Summary:背景与目的新辅助化疗是肺癌治疗的新进展，西妥昔单和合塞来昔布均是近年来新辅助化疗的常用药物，本研究旨在探讨表皮生长因子受体（epithelialgrowthfactorreceptor,EGFR）单克隆抗体西妥昔单抗（Cetux-imab）联合环氧合酶2（cyclooxygenase．2，COX-2）抑制剂塞来昔布对肺腺癌A549细胞株凋亡和KDR、AQP1表达的影响。方法A549细胞培养于RPMI-1640培养液中，实验分为正常对照组、西妥昔单抗1nmol／L组、塞来昔布25omol／L组、西妥昔单抗1nmol／L＋塞来昔布25μmol／L组。药物干预细胞48h后，采用四甲基偶氮唑盐比色法测定细胞抑制率；采用流式细胞术测定细胞周期分布的变化；用Transwelldx室法检测药物处理前后细胞侵袭力的变化。采用RT-PCR、Westernblot检测KDR、A0．P1基因和蛋白的表达情况。结果西妥昔单抗和塞来昔布对A549细胞增殖有明显的抑制作用，两制剂联合作用时抑制作用更强（P〈0．01）。西妥昔单抗和塞来昔布均可诱导细胞凋亡，联合作用后细胞凋亡率更高（P〈0．01）；联合用药与单独用药相比，可使细胞发生明显的G1期阻滞（P〈0．01），进一步下调了KDR、AQP1基因和蛋白的表达（P〈0．05），细胞侵袭力明显降低。结论西妥昔单抗和塞来昔布联合应用具有协同作用，可进一步抑制细胞的生长和迁移，下调了KDR、AQP1基因和蛋白的表达提示两药联合使用临床肺癌治疗可能具有很大的潜力。
Bibliography:Cetuximab; Celecoxib; Cell apoptosis; KDR; AQP1
Honggang XIA, Jianfei YE, Hongyu BAT, Changli WANG（1 Graduate School of Tianjin Medical University, Tianjin 300070, China; 2Department of Thoracic Surgery, Tianjin Dagang Oil Field General Hospital, Tianjin 300280, China; 3Department of Thoracic Surgery, Tianjin Tumour Hospital, Tianjin 300060, China）
Background and objective Neoadjuvant chemotherapy is a new development in the treatment of lung cancer. In recent years, cetuximab and celecoxib have been commonly used in this procedure. This study aims to explore the effect of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer A549 cells. Method The cells were cultured in RPMI-1640 and then divided into four groups： control group, 1 nmol/L cetuximab group, 25 μmol/ L celecoxib group, and 1 nmol/L cetuximab＋25 μmol/L celecoxib group. The treatment time was 48 h. The mRNA and protein expression levels of KDR and AQP1 were detected by RT-PCR and Western blot, respectively. The ap
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2013.12.02